PŘEHLEDOVÉ ČLÁNKY Hypolipidemická terapie v těhotenství | 175 / Vnitř Lék. 2026;72(3):171-175 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Mulder JWCM, Kusters DM, Roeters Van Lennep JE, Hutten BA. Lipid metabolism during pregnancy: consequences for mother and child. Curr Opin Lipidol. 2024;35(3):133-140. doi:10.1097/MOL.0000000000000927. 2. Národní Registr Reprodukčního Zdraví. https://www.uzis.cz/index.php?pg=registrysber-dat--narodni-zdravotni-registry--narodni-registr-reprodukcniho-zdravi 3. Ascarelli M, Grider A, Hsu H. Acute myocardial infarction during pregnancy managed with immediate percutaneous transluminal coronary angioplasty. Obstet Gynecol. 1996;88(4):655-657. doi:10.1016/0029-7844(96)00288-8. 4. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol. 2016;10(5):1081-1090. doi:10.1016/j.jacl.2016. 07. 002. 5. Cao L, Du Y, Zhang M, et al. High maternal blood lipid levels during early pregnancy are associated with increased risk of congenital heart disease in offspring. Acta Obstet Gynecol Scand. 2021;100(10):1806-1813. doi:10.1111/aogs.14225. 6. Papazoglou AS, Moysidis DV, Panagopoulos P, et al. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2022;35(25):7685-7694. doi:10.108 0/14767058.2021.1960968. 7. Ryan EA, Enns L. Role of Gestational Hormones in the Induction of Insulin Resistance*. J Clin Endocrinol Metab. 1988;67(2):341-347. doi:10.1210/jcem-67-2-341. 8. Martin-Hidalgo A, Holm C, Belfrage P, Schotz MC, Herrera E. Lipoprotein lipase and hormone-sensitive lipase activity and mRNA in rat adipose tissue during pregnancy. Am J Physiol-Endocrinol Metab. 1994;266(6):E930-E935. doi:10.1152/ajpendo.1994.266. 6. E930. 9. Wiznitzer A, Mayer A, Novack V, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201(5):482.e1-482.e8. doi:10.1016/j.ajog.2009. 05. 032. 10. Golwala S, Dolin CD, Nemiroff R, et al. Feasibility of Lipid Screening During First Trimester of Pregnancy to Identify Women at Risk of Severe Dyslipidemia. J Am Heart Assoc. 2023;12(10):e028626. doi:10.1161/JAHA.122.028626. 11. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197. 12. Healthy Pregnancy: What Foods to Eat When Pregnant. Last Updated 01 August 2021. https://www.eufic.org/en/healthy-living/article/healthy-pregnancy-what-foods-to-eat- -when-pregnant (accessed on 19 July 2025). 13. Davenport MH, Kathol AJ, Mottola MF, et al. Prenatal exercise is not associated with fetal mortality: a systematic review and meta-analysis. Br J Sports Med. 2019;53(2):108-115. doi:10.1136/bjsports-2018-099773. 14. De Backer J, Haugaa KH, Hasselberg NE, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/ eurheartj/ehaf193. 15. Jadrnickova P, Vaclavik J, Jarkovsky J, Zouharova A. Maternal and fetal outcomes of various lipid-lowering treatment regimens during pregnancy: insights from the czech national registry 2012-2023. Eur Heart J. 2025;46(Supplement_1):ehaf784.3444. doi:10.1093/ eurheartj/ehaf784.3444. 16. FDA. Cholestyramine powder for suspension. https://fda.report/DailyMed/ac385fd9-fb8c-461f-959c-322c38f4515e. 17. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy. Gastroenterology. 2005;129(3):894-901. doi:10.1053/j.gastro.2005. 06. 019. 18. Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. BJOG Int J Obstet Gynaecol. 1995;102(2):169-170. doi:10.1111/j.1471-0528.1995.tb09077.x. 19. Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol. 1994;74(11):1109-1112. doi:10.1016/0002-9149(94)90461-8. 20. Bláha V, Zadák Z, Bláha M, et al. (Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis). Cas Lek Cesk. 1998;137(14):424-429. 21. Makino H, Koezuka R, Tamanaha T, et al. Familial Hypercholesterolemia and Lipoprotein Apheresis. J Atheroscler Thromb. 2019;26(8):679-687. doi:10.5551/jat.RV17033. 22. Bláha M, Veletová K, Blaha V, Lánská M, Žák P. Pregnancy in homozygous familial hypercholesterolemia–A case series. Ther Apher Dial. 2022;26(S1):89-96. doi:10.1111/1744-9987.13841. 23. Ogura M, Makino H, Kamiya C, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. Atherosclerosis. 2016;254:179-183. doi:10.1016/j.atherosclerosis.2016. 10. 018. 24. Marlęga-Linert J, Wartecka-Zielińska K, Wydra D, Fijałkowski M, Gruchała M, Mickiewicz A. Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia. Front Med. 2023;10:1190446. doi:10.3389/fmed.2023.1190446. 25. FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy. Published online August 14, 2024. https://www.fda.gov/drugs/fda- -drug-safety-podcasts/fda-requests-removalstrongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy. 26. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG Int J Obstet Gynaecol. 2013;120(4):463-471. doi:10.1111/1471-0528.12066. 27. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26(7):843-852. doi:10.1002/pds.4176. 28. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015;350(mar17 10):h1035-h1035. doi:10.1136/bmj.h1035. 29. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251-261. doi:10.1016/j.atherosclerosis.2012. 02. 016. 30. Wild R, Feingold KR. Effect of Pregnancy on Lipid Metabolism and Lipoprotein Levels. (Updated 2023 Mar 3). In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext (Internet). https://www.ncbi.nlm.nih.gov/books/NBK498654/. 31. Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047-5057. doi:10.1093/eurheartj/ehac615. 32. Ardissino M, Slob EAW, Reddy RK, et al. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations. Eur J Prev Cardiol. 2024;31(8):955-965. doi:10.1093/eurjpc/zwad402. 33. Noseda R, Bedussi F, Panchaud A, Ceschi A. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clin Pharmacol Ther. 2024;116(2):346-350. doi:10.1002/cpt.3269. 34. Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393(21):2119-2130. doi:10.1056/NEJMoa2511778. 35. Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Pregnancy and Childbirth Group, ed. Cochrane Database Syst Rev. 2018;2018(11). doi:10.1002/14651858.CD003402.pub3. 36. Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e664-e684. doi:10.1016/j.jacl.2024. 05. 005. 37. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):18. doi:10.1016/j.atherosclerosis.2009. 03. 008. 38. Grady J, Clifford C, Treadwell MC, Parikh ND, Satishchandran A. Use of fenofibrate for intrahepatic cholestasis of pregnancy. J Hepatol. 2023;79(2):e84-e86. doi:10.1016/j.jhep.2023. 04. 014. 39. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11). doi:10.1161/CIR.0000000000000678. 40. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Heart Group, ed. Cochrane Database Syst Rev. 2016;2017(3). doi:10.1002/14651858.CD009753.pub2. 41. Wanninayake S, Ochoa-Ferraro A, Patel K, Ramachandran R, Wierzbicki AS, Dawson C. Two successful pregnancies in patients taking Volanesorsen for familial chylomicronemia syndrome. JIMD Rep. 2024;65(4):249-254. doi:10.1002/jmd2.12435.
RkJQdWJsaXNoZXIy NDA4Mjc=